Elanco Animal Health reported first quarter 2024 financial results, with revenue of $1,205 million and a reported EPS of $0.06. The company's performance was impacted by a shift in customer purchasing related to the ERP Blackout in 2023. Elanco is updating its full year 2024 financial guidance to reflect first quarter outperformance offset by expected unfavorable impact of foreign exchange rates.
Revenue reached $1,205 million.
Reported net income was $32 million, with an adjusted net income of $167 million.
Adjusted EBITDA stood at $294 million, representing 24.4% of revenue.
Reported EPS was $0.06, while adjusted EPS was $0.34.
Elanco is updating financial guidance for the full year 2024 and providing guidance for the second quarter of 2024. The company now anticipates revenue between $4,460 and $4,515 million and adjusted EPS of $0.88 to $0.96 for the full year. For the second quarter of 2024, the company anticipates revenue between $1,145 and $1,170 million and adjusted EPS between $0.23 and $0.26.
Visualization of income flow from segment revenue to net income